The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|October 24, 2011
Compliance Insight Podcasts: Implementing Process Validation - Episode 3
Advertisement
Step-by-Step Validation for Bio/Pharmaceuticals: Meeting New Regulatory Expectations
Optimizing cleaning validation - Episode 3
Listeners will walk away with knowledge of how to prevent cross-contamination in bio/pharmaceutical manufacturing using a risk-based approach, including how to handle unique challenges that occur with continuous processing and revalidation. Best practices and regulatory expectations from ICH Q9 guideline, the ISPE Risk MaPP guideline, and the ASTM 2500 Standard Guide for Specification, Design, and Verification for Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment will be addressed.
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement